Marinobufagenin, an endogenous inhibitor of alpha-1 Na/K-ATPase, is a novel factor in pathogenesis of diabetes mellitus.
Bagrov
Y Y
YY
Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St Petersburg, Russia.
Manusova
N B
NB
Egorova
I A
IA
Frolova
E V
EV
Fedorova
O V
OV
Bagrov
A Y
AY
D000818:Animals; D002018:Bufanolides / Q000378:metabolism* / Q000652:urine; D002298:Cardenolides / Q000378:metabolism; D003920:Diabetes Mellitus / Q000209:etiology* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000378:metabolism*; D004912:Erythrocytes / Q000201:enzymology; D006801:Humans; D008297:Male; D010042:Ouabain / Q000378:metabolism; D020033:Protein Isoforms / Q000378:metabolism; D051381:Rats; D012503:Saponins / Q000378:metabolism; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors*
D002018:Bufanolides; D002298:Cardenolides; D004791:Enzyme Inhibitors; D020033:Protein Isoforms; D012503:Saponins; C034504:digoxin-like factors; C093896:marinobufagenin; D010042:Ouabain; D000254:Sodium-Potassium-Exchanging ATPase